Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
Activity